stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Free cash flow margin
Summit Therapeutics PLC's free cash flow margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −5,986.7% (fiscal 2022) to 524.3% (fiscal 2017); the current reading is higher than 87% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 5,986.67 |
| FY2022 | −5,986.7% | (1,957.21) |
| FY2021 | −4,029.5% | 1,613.80 |
| FY2020 | −5,643.3% | (2,803.69) |
| FY2019 | −2,839.6% | (2,776.98) |
| FY2019 | −62.6% | 56.16 |
| FY2018 | −118.8% | (59.08) |
| FY2018 | −59.7% | (584.01) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | 49.8% |
| ASND Ascendis Pharma A/S compare | 32.0% |
| TECH Bio-Techne Corp compare | 21.7% |
| BMRN BioMarin Pharmaceutical Inc. compare | 15.3% |
| JAZZ Jazz Pharmaceuticals PLC compare | 14.1% |
| PCVX Vaxcyte, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC | 0.00% |
| KYMR Kymera Therapeutics, Inc. compare | 0.00% |
| BBIO BridgeBio Pharma, Inc. compare | −39.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement